We are live on ! Find out more
DC

Decheng Capital Portfolio holdings

AUM $661M
1-Year Est. Return 299.97%
This Fund
S&P 500
This Quarter Est. Return
-22.22%
1 Year Est. Return
+299.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$326M
AUM Growth
-$419M
Cap. Flow
-$295M
Cap. Flow %
-90.42%
Top 10 Hldgs %
86.05%
Holding
28
New
6
Increased
3
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$21.2M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$10.8M
3
NAMS icon
NewAmsterdam Pharma
NAMS
+$8.02M
4
MRUS
Merus
MRUS
+$3.74M
5
VERA icon
Vera Therapeutics
VERA
+$2.77M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$330M
2
TXG icon
10x Genomics
TXG
+$7.35M
3
ILMN icon
Illumina
ILMN
+$2.68M
4
HLTH
Cue Health Inc. Common Stock
HLTH
+$1.7M
5
WHWK
Whitehawk Therapeutics
WHWK
+$1.23M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.41B
$172M 52.81%
5,458,810
– –
NUVB icon
2
Nuvation Bio
NUVB
$2.33B
$20.3M 6.22%
+6,950,239
New +$21.2M
RCUS icon
3
Arcus Biosciences
RCUS
$3.4B
$13.2M 4.06%
869,790
– –
ZNTL icon
4
Zentalis Pharmaceuticals
ZNTL
$329M
$12.6M 3.85%
3,070,442
+970,859
+46% +$10.8M
KRYS icon
5
Krystal Biotech
KRYS
$10.7B
$12.1M 3.7%
65,772
– –
BYSI icon
6
BeyondSpring
BYSI
$48.7M
$11.9M 3.65%
4,958,143
– –
ILMN icon
7
Illumina
ILMN
$29.2B
$11.4M 3.48%
108,767
-23,914
-18% -$2.68M
MRUS
8
DELISTED
Merus
MRUS
$10.6M 3.25%
179,098
+77,300
+76% +$3.74M
PHAT icon
9
Phathom Pharmaceuticals
PHAT
$930M
$8.76M 2.68%
850,000
– –
NAMS icon
10
NewAmsterdam Pharma
NAMS
$3.27B
$7.68M 2.35%
+400,000
New +$8.02M
MLTX icon
11
MoonLake Immunotherapeutics
MLTX
$1.59B
$7.33M 2.24%
166,600
– –
FDMT icon
12
4D Molecular Therapeutics
FDMT
$515M
$7.3M 2.24%
347,835
– –
CRNX icon
13
Crinetics Pharmaceuticals
CRNX
$8.88B
$7.07M 2.17%
157,958
– –
CYTK icon
14
Cytokinetics
CYTK
$10.8B
$5.1M 1.56%
94,043
– –
LEGN icon
15
Legend Biotech
LEGN
$3.68B
$4.37M 1.34%
98,558
+12,195
+14% +$563K
AURA icon
16
Aura Biosciences
AURA
$729M
$3.9M 1.19%
515,555
– –
EQ icon
17
Equillium
EQ
$147M
$3.08M 0.94%
4,447,308
– –
WGS icon
18
GeneDx Holdings
WGS
$1.84B
$2.71M 0.83%
103,604
– –
VERA icon
19
Vera Therapeutics
VERA
$2.39B
$2.52M 0.77%
+69,767
New +$2.77M
PYXS icon
20
Pyxis Oncology
PYXS
$184M
$1.08M 0.33%
326,810
– –
ATRC icon
21
AtriCure
ATRC
$2.02B
$610K 0.19%
26,797
– –
GRAL
22
GRAIL Inc
GRAL
$2.76B
$279K 0.09%
+18,127
New +$294K
NUVB.WS
23
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$103K 0.03%
+646,057
New +$132K
ACLX
24
DELISTED
Arcellx
ACLX
$65K 0.02%
+1,177
New +$64K
TXG icon
25
10x Genomics
TXG
$5.97B
– –
-195,835
Closed -$7.35M
1
2

Similar funds

FAM
Fulcrum Asset Management London, United Kingdom $662M AUM 48.09% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
HIG
Heritage Investment Group Pompano Beach, Florida $661M AUM 14.84% 1-Year Est. Return
RCG
Regatta Capital Group El Segundo, California $661M AUM 17.85% 1-Year Est. Return
FM
Freemont Management Vaud, Switzerland $661M AUM 60.48% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
AWA
Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return
UCMOK
United Capital Management of KS Salina, Kansas $660M AUM 50.85% 1-Year Est. Return

Decheng Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Decheng Capital held 28 positions worth $326M, down 56% from $746M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Decheng Capital withdrew a net $295M in Q2 2024, closing 4 positions and reducing 1 holding. Its most notable exit was Alpine Immune Sciences Inc, an estimated $330M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Decheng Capital opened a new position in Nuvation Bio worth $20.3M.

  • Decheng Capital's largest Q2 2024 buy was Nuvation Bio: 6,950,239 shares worth $20.3M.
  • Decheng Capital added most to Zentalis Pharmaceuticals in Q2 2024, an estimated $10.8M increase.
  • Decheng Capital's biggest Q2 2024 reduction was Illumina, cutting an estimated $2.68M.
  • Decheng Capital fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $330M.
  • Decheng Capital's ten largest holdings make up 86% of its $326M portfolio in Q2 2024.
  • Decheng Capital opened 6 new positions and closed 4 in Q2 2024.
  • Decheng Capital's portfolio value fell 56% quarter-over-quarter to $326M.

Based on Decheng Capital's 13F filing for Q2 2024, filed 14 Aug 2024.